APA (7th ed.) Citation

Tredan, O., Saada, E., Dalban, C., Cousin, S., Le Cesne, A., Italiano, A., . . . Blay, J. (2025). 216eP MegaMOST - A multicenter, open-label, molecularly selected bayesian phase II platform trial in advanced or metastatic solid tumors: Final analysis of the trametinib cohort. Annals of Oncology, 36, S291. https://doi.org/10.1016/j.annonc.2025.08.648

Chicago Style (17th ed.) Citation

Tredan, O., et al. "216eP MegaMOST - A Multicenter, Open-label, Molecularly Selected Bayesian Phase II Platform Trial in Advanced or Metastatic Solid Tumors: Final Analysis of the Trametinib Cohort." Annals of Oncology 36 (2025): S291. https://doi.org/10.1016/j.annonc.2025.08.648.

MLA (9th ed.) Citation

Tredan, O., et al. "216eP MegaMOST - A Multicenter, Open-label, Molecularly Selected Bayesian Phase II Platform Trial in Advanced or Metastatic Solid Tumors: Final Analysis of the Trametinib Cohort." Annals of Oncology, vol. 36, 2025, p. S291, https://doi.org/10.1016/j.annonc.2025.08.648.